226 related articles for article (PubMed ID: 36332622)
21. Dependence on MUC1-C in Progression of Neuroendocrine Prostate Cancer.
Kufe D
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835130
[TBL] [Abstract][Full Text] [Related]
22. Molecular model for neuroendocrine prostate cancer progression.
Chen R; Dong X; Gleave M
BJU Int; 2018 Oct; 122(4):560-570. PubMed ID: 29569310
[TBL] [Abstract][Full Text] [Related]
23. N-Myc-mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer.
Berger A; Brady NJ; Bareja R; Robinson B; Conteduca V; Augello MA; Puca L; Ahmed A; Dardenne E; Lu X; Hwang I; Bagadion AM; Sboner A; Elemento O; Paik J; Yu J; Barbieri CE; Dephoure N; Beltran H; Rickman DS
J Clin Invest; 2019 Jul; 129(9):3924-3940. PubMed ID: 31260412
[TBL] [Abstract][Full Text] [Related]
24. Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.
Wang J; Li J; Yin L; Pu T; Wei J; Karthikeyan V; Lin TP; Gao AC; Wu BJ
Oncogene; 2022 Sep; 41(37):4307-4317. PubMed ID: 35986103
[TBL] [Abstract][Full Text] [Related]
25. Foxa1 and Foxa2 interact with the androgen receptor to regulate prostate and epididymal genes differentially.
Yu X; Gupta A; Wang Y; Suzuki K; Mirosevich J; Orgebin-Crist MC; Matusik RJ
Ann N Y Acad Sci; 2005 Dec; 1061():77-93. PubMed ID: 16467259
[TBL] [Abstract][Full Text] [Related]
26. FOXA2-KIT-driven lineage plasticity in NEPC.
Masone MC
Nat Rev Urol; 2023 Jan; 20(1):8. PubMed ID: 36477218
[No Abstract] [Full Text] [Related]
27. Identification of Novel Diagnosis Biomarkers for Therapy-Related Neuroendocrine Prostate Cancer.
Zhang C; Qian J; Wu Y; Zhu Z; Yu W; Gong Y; Li X; He Z; Zhou L
Pathol Oncol Res; 2021; 27():1609968. PubMed ID: 34646089
[No Abstract] [Full Text] [Related]
28. KIT as a therapeutic target in neuroendocrine prostate cancer.
Azad AA; Kostos L; Agarwal N
Cancer Cell; 2022 Nov; 40(11):1266-1268. PubMed ID: 36332623
[TBL] [Abstract][Full Text] [Related]
29. Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.
Qi J; Nakayama K; Cardiff RD; Borowsky AD; Kaul K; Williams R; Krajewski S; Mercola D; Carpenter PM; Bowtell D; Ronai ZA
Cancer Cell; 2010 Jul; 18(1):23-38. PubMed ID: 20609350
[TBL] [Abstract][Full Text] [Related]
30. Activated ALK Cooperates with N-Myc via Wnt/β-Catenin Signaling to Induce Neuroendocrine Prostate Cancer.
Unno K; Chalmers ZR; Pamarthy S; Vatapalli R; Rodriguez Y; Lysy B; Mok H; Sagar V; Han H; Yoo YA; Ku SY; Beltran H; Zhao Y; Abdulkadir SA
Cancer Res; 2021 Apr; 81(8):2157-2170. PubMed ID: 33637566
[TBL] [Abstract][Full Text] [Related]
31. The evolutionarily conserved long non-coding RNA LINC00261 drives neuroendocrine prostate cancer proliferation and metastasis via distinct nuclear and cytoplasmic mechanisms.
Mather RL; Parolia A; Carson SE; Venalainen E; Roig-Carles D; Jaber M; Chu SC; Alborelli I; Wu R; Lin D; Nabavi N; Jachetti E; Colombo MP; Xue H; Pucci P; Ci X; Hawkes C; Li Y; Pandha H; Ulitsky I; Marconett C; Quagliata L; Jiang W; Romero I; Wang Y; Crea F
Mol Oncol; 2021 Jul; 15(7):1921-1941. PubMed ID: 33793068
[TBL] [Abstract][Full Text] [Related]
32. Alternative RNA splicing of the GIT1 gene is associated with neuroendocrine prostate cancer.
Lee AR; Gan Y; Xie N; Ramnarine VR; Lovnicki JM; Dong X
Cancer Sci; 2019 Jan; 110(1):245-255. PubMed ID: 30417466
[TBL] [Abstract][Full Text] [Related]
33.
Bhagirath D; Yang TL; Tabatabai ZL; Majid S; Dahiya R; Tanaka Y; Saini S
Clin Cancer Res; 2019 Nov; 25(21):6532-6545. PubMed ID: 31371344
[TBL] [Abstract][Full Text] [Related]
34. Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.
Tsai HK; Lehrer J; Alshalalfa M; Erho N; Davicioni E; Lotan TL
BMC Cancer; 2017 Nov; 17(1):759. PubMed ID: 29132337
[TBL] [Abstract][Full Text] [Related]
35. MCM2-7 complex is a novel druggable target for neuroendocrine prostate cancer.
Hsu EC; Shen M; Aslan M; Liu S; Kumar M; Garcia-Marques F; Nguyen HM; Nolley R; Pitteri SJ; Corey E; Brooks JD; Stoyanova T
Sci Rep; 2021 Jun; 11(1):13305. PubMed ID: 34172788
[TBL] [Abstract][Full Text] [Related]
36. DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2.
Kaarijärvi R; Kaljunen H; Nappi L; Fazli L; Kung SHY; Hartikainen JM; Paakinaho V; Capra J; Rilla K; Malinen M; Mäkinen PI; Ylä-Herttuala S; Zoubeidi A; Wang Y; Gleave ME; Hiltunen M; Ketola K
Commun Biol; 2024 Jan; 7(1):108. PubMed ID: 38238517
[TBL] [Abstract][Full Text] [Related]
37. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance.
Beltran H; Hruszkewycz A; Scher HI; Hildesheim J; Isaacs J; Yu EY; Kelly K; Lin D; Dicker A; Arnold J; Hecht T; Wicha M; Sears R; Rowley D; White R; Gulley JL; Lee J; Diaz Meco M; Small EJ; Shen M; Knudsen K; Goodrich DW; Lotan T; Zoubeidi A; Sawyers CL; Rudin CM; Loda M; Thompson T; Rubin MA; Tawab-Amiri A; Dahut W; Nelson PS
Clin Cancer Res; 2019 Dec; 25(23):6916-6924. PubMed ID: 31363002
[TBL] [Abstract][Full Text] [Related]
38. Smoothened loss is a characteristic of neuroendocrine prostate cancer.
Wang L; Li H; Li Z; Li M; Tang Q; Wu C; Lu Z
Prostate; 2021 Jun; 81(9):508-520. PubMed ID: 33955576
[TBL] [Abstract][Full Text] [Related]
39. Nerve growth factor interacts with CHRM4 and promotes neuroendocrine differentiation of prostate cancer and castration resistance.
Chen WY; Wen YC; Lin SR; Yeh HL; Jiang KC; Chen WH; Lin YS; Zhang Q; Liew PL; Hsiao M; Huang J; Liu YN
Commun Biol; 2021 Jan; 4(1):22. PubMed ID: 33398073
[TBL] [Abstract][Full Text] [Related]
40. Icaritin suppresses development of neuroendocrine differentiation of prostate cancer through inhibition of IL-6/STAT3 and Aurora kinase A pathways in TRAMP mice.
Sun F; Zhang ZW; Tan EM; Lim ZLR; Li Y; Wang XC; Chua SE; Li J; Cheung E; Yong EL
Carcinogenesis; 2016 Jul; 37(7):701-711. PubMed ID: 27207661
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]